Weekly Digest: Commercial Research Optimization

Check out some of our latest content around a recent 3-part series on commercial resource optimization.

Mastering New Commercialization Dynamics with an Adaptive Playbook

While most will agree that change is inevitable, what we’re seeing play out in the biopharma market is a game-changing transition of an unparalleled degree. Difficult capital markets, the Inflation Reduction Act (IRA), rising costs and sinking returns means the path to commercializing an asset looks very different and is much more difficult.??

The new landscape in biopharma is one where survival doesn’t guarantee unlocking the value of your asset or product. Growth requires discarding the old playbook and embracing the fact that the path to success could be radically different. Absorbing market jolts requires flexibility; the higher level you have, the more resourceful you can be to adapt to market fluctuations and stay competitive.??

Read the full article here for key takeaways and important considerations to ensure commercialization success.??

Allocating Commercial Resources to Elevate Omnichannel Marketing

Engaging customers in a stable market is multi-faceted and complex. A fluctuating market adds a layer of complexity to doing so, particularly with their preferences constantly evolving. According to a recent Syneos Health? customer engagement benchmarking study, market variations have required most companies surveyed to downsize and restructure. To realign, organizations must identify the right balance of digital and face-to-face strategies for the most effective connection. In most cases they will need to do so with fewer resources and additional economic challenges.

Read the full article here to understand the importance of creating a flexible omnichannel model in a dynamic drug development market that meets diverse customer needs.?

Extending Your Established Brand’s Value in a Challenging Macroeconomic Environment

Nine out of ten biopharma executives are worried about the economic environment, citing inflation, drug pricing and reimbursement constraints in the years ahead. Overlooking an opportunity to optimize a mature brand is a common misstep for companies in a market where the current economic challenges are vast. But, in daunting conditions, focusing on delivering value is more critical than ever. Cost-cutting is judicious but only achieves so much.

Download the white paper here to learn how allowing an established brand to ‘run its course’ by leaving untapped value on the table is counterproductive and how to instead evaluate, resource and scale to access the full revenue potential of a mature brand.

The?Syneos Health Insights Hub?generates future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment. Driven by dynamic research, our perspectives are informed by our insights-driven product development model and crafted by subject matter experts focused on real answers to customer challenges to help guide decision making and investment.